Xue‐Chun Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xue‐Chun Yu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Chen Zhang
Department of Gastroenterology and Hepatology Anyang Municipal People's Hospital Anyang Henan China
2 shared publications - Jing Ma
Department of Gastroenterology and Hepatology People's Hospital of Zhengzhou University, Henan Provincial People's Hospital Zhengzhou Henan China
2 shared publications - Ruo‐Bing Hu
Department of Gastroenterology and Hepatology People's Hospital of Zhengzhou University, Henan Provincial People's Hospital Zhengzhou Henan China
2 shared publications - Song-Ze Ding
Department of Gastroenterology and Hepatology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China
2 shared publications - Wei Xiao
Department of Gastroenterology and Hepatology People's Hospital of Zhengzhou University, Henan Provincial People's Hospital Zhengzhou Henan China
2 shared publications - Ya‐Bin Qi
Department of Gastroenterology and Hepatology People's Hospital of Zhengzhou University, Henan Provincial People's Hospital Zhengzhou Henan China
2 shared publications
Latest Publications
- 19 July 2024
- Published by Wiley in Helicobacter
- Vol. 29 (4) , e13114
Improved Patient Adherence to Family‐Based Helicobacter pylori Infection Control and Management Strategy in Central China and Its Influencing Factors
Background: Patient adherence status to the newly introduced family‐based Helicobacter pylori ( H. pylori ) infection control and management strategy remains unclear, so are its influencing factors. We aim to investigate family members' adherence and its influencing factors during the family‐based H. pylori infection management practice for related disease prevention. Materials and Methods: Based on our previously family‐based H. pylori survey in 2021, 282 families including 772 individuals were followed up 2 years after the initial survey to compare if the investigation and education might improve family member's adherence. The participant's adherence to H. pylori infection awareness, retest, treatment, publicity, gastroscopy, and hygiene habits were followed up, and their influencing factors were also analyzed. Results: The overall participant's adherence to recommendations on H. pylori awareness, retest, treatment, publicity, gastroscopy, and hygiene habits were 77% (187/243), 67.3% (138/205), 60.1% (211/351), 46.5% (107/230), 45.6% (159/349), and 39.1% (213/545), respectively; and all showed improvements compared with their prior survey stages. The top reasons for rejection to treatment, retest, and gastroscopy were forgetting or unaware of H. pylori infection (30.3%), busy (32.8%), and asymptomatic (67.9%), respectively. Independent risk factor for low adherence to treatment was occupation (e.g., staff: OR 4.49, 95% CI 1.34–15.10). Independent favorable factors for treatment adherence were individuals at the ages of 18–44 years (OR 0.19, 95% CI 0.04–0.89) and had a large family size (e.g., four family members: OR 0.15, 95% CI 0.06–0.41); for retest adherence, it was individuals at the ages of 60–69 years (OR 0.23, 95% CI 0.06–0.97); for gastroscopy adherence, it was individuals at the age of 60–69 years (OR 0.46, 95% CI 0.28–0.75), and with gastrointestinal symptoms (OR 0.57, 95% CI 0.36–0.90). Conclusions: Family‐based H. pylori management increases individual adherence to treatment, retest, and awareness, and there are also improved adherence to gastroscopy, publicity, and personal hygiene recommendations; further efforts are required to enhance the individual adherence rate for related disease prevention.
- 19 July 2024
- Published by Wiley in Helicobacter
- Vol. 29 (4) , e13114
Improved Patient Adherence to Family‐Based Helicobacter pylori Infection Control and Management Strategy in Central China and Its Influencing Factors
Background: Patient adherence status to the newly introduced family‐based Helicobacter pylori ( H. pylori ) infection control and management strategy remains unclear, so are its influencing factors. We aim to investigate family members' adherence and its influencing factors during the family‐based H. pylori infection management practice for related disease prevention. Materials and Methods: Based on our previously family‐based H. pylori survey in 2021, 282 families including 772 individuals were followed up 2 years after the initial survey to compare if the investigation and education might improve family member's adherence. The participant's adherence to H. pylori infection awareness, retest, treatment, publicity, gastroscopy, and hygiene habits were followed up, and their influencing factors were also analyzed. Results: The overall participant's adherence to recommendations on H. pylori awareness, retest, treatment, publicity, gastroscopy, and hygiene habits were 77% (187/243), 67.3% (138/205), 60.1% (211/351), 46.5% (107/230), 45.6% (159/349), and 39.1% (213/545), respectively; and all showed improvements compared with their prior survey stages. The top reasons for rejection to treatment, retest, and gastroscopy were forgetting or unaware of H. pylori infection (30.3%), busy (32.8%), and asymptomatic (67.9%), respectively. Independent risk factor for low adherence to treatment was occupation (e.g., staff: OR 4.49, 95% CI 1.34–15.10). Independent favorable factors for treatment adherence were individuals at the ages of 18–44 years (OR 0.19, 95% CI 0.04–0.89) and had a large family size (e.g., four family members: OR 0.15, 95% CI 0.06–0.41); for retest adherence, it was individuals at the ages of 60–69 years (OR 0.23, 95% CI 0.06–0.97); for gastroscopy adherence, it was individuals at the age of 60–69 years (OR 0.46, 95% CI 0.28–0.75), and with gastrointestinal symptoms (OR 0.57, 95% CI 0.36–0.90). Conclusions: Family‐based H. pylori management increases individual adherence to treatment, retest, and awareness, and there are also improved adherence to gastroscopy, publicity, and personal hygiene recommendations; further efforts are required to enhance the individual adherence rate for related disease prevention.
- 15 June 2022
- Published by Wiley in Helicobacter
- Vol. 27 (4) , e12911
Both family‐based Helicobacter pylori infection control and management strategy and screen‐and‐treat strategy are cost‐effective for gastric cancer prevention
Background: Helicobacter pylori (H. pylori) infection and its related diseases are substantial public health burden for highly infected areas. Recently, a novel family‐based H. pylori infection control and management (FBCM) strategy is introduced for H. pylori infection prevention and control. However, its cost‐effectiveness has not been evaluated. We conducted this health economic evaluation to investigate the cost‐effectiveness of FBCM, screen‐and‐treat, and no‐screen strategies in Chinese population.Materials and Methods: Cost‐effectiveness analysis was performed using decision tree and Markov model. Parameters required for the model were from published literatures and public databases, including health state utility, screening characteristics, treatment effectiveness, and medical costs for the three strategies. Outcomes were cost, quality‐adjusted life year (QALY), incremental cost‐effectiveness ratio (ICER). Uncertainty analysis was performed to verify the robustness of this model.Results: To prevent gastric cancer in a cohort of 1 million asymptomatic Chinese families, FBCM and screen‐and‐treat strategies prevented 1010 and 1201 new gastric cancer cases, reduced 2809 and 3339 gastric cancer‐related death, and saved 956,971 and 1,137,549 QALYs, respectively, when compared with no‐screen strategy. Cost‐effectiveness analysis showed that FBCM strategy cost $9.18/QALY, and screen‐and‐treat strategy cost $12.08/QALY for gastric cancer prevention when compared with no‐screen strategy. One‐way sensitivity analysis revealed that screening from younger age by both strategies are more cost‐effective. When compared with FBCM strategy, screen‐and‐treat strategy saved 5.98% gastric cancer cases and 5.78% of gastric cancer deaths, but costed $9348 to reduce a gastric cancer case. Results are not sensitive to any variables, and probabilistic sensitivity analysis confirmed robustness of the results.Conclusions: Both FBCM and screen‐and‐treat strategies are cost‐effective for gastric cancer prevention compared with no‐screen strategy. Since FBCM is more practical and convenient, it may be an efficient and excellent cost‐effective strategy for gastric cancer prevention in H. pylori and gastric cancer prevalent areas.
- 15 June 2022
- Published by Wiley in Helicobacter
- Vol. 27 (4) , e12911
Both family‐based Helicobacter pylori infection control and management strategy and screen‐and‐treat strategy are cost‐effective for gastric cancer prevention
Background: Helicobacter pylori (H. pylori) infection and its related diseases are substantial public health burden for highly infected areas. Recently, a novel family‐based H. pylori infection control and management (FBCM) strategy is introduced for H. pylori infection prevention and control. However, its cost‐effectiveness has not been evaluated. We conducted this health economic evaluation to investigate the cost‐effectiveness of FBCM, screen‐and‐treat, and no‐screen strategies in Chinese population.Materials and Methods: Cost‐effectiveness analysis was performed using decision tree and Markov model. Parameters required for the model were from published literatures and public databases, including health state utility, screening characteristics, treatment effectiveness, and medical costs for the three strategies. Outcomes were cost, quality‐adjusted life year (QALY), incremental cost‐effectiveness ratio (ICER). Uncertainty analysis was performed to verify the robustness of this model.Results: To prevent gastric cancer in a cohort of 1 million asymptomatic Chinese families, FBCM and screen‐and‐treat strategies prevented 1010 and 1201 new gastric cancer cases, reduced 2809 and 3339 gastric cancer‐related death, and saved 956,971 and 1,137,549 QALYs, respectively, when compared with no‐screen strategy. Cost‐effectiveness analysis showed that FBCM strategy cost $9.18/QALY, and screen‐and‐treat strategy cost $12.08/QALY for gastric cancer prevention when compared with no‐screen strategy. One‐way sensitivity analysis revealed that screening from younger age by both strategies are more cost‐effective. When compared with FBCM strategy, screen‐and‐treat strategy saved 5.98% gastric cancer cases and 5.78% of gastric cancer deaths, but costed $9348 to reduce a gastric cancer case. Results are not sensitive to any variables, and probabilistic sensitivity analysis confirmed robustness of the results.Conclusions: Both FBCM and screen‐and‐treat strategies are cost‐effective for gastric cancer prevention compared with no‐screen strategy. Since FBCM is more practical and convenient, it may be an efficient and excellent cost‐effective strategy for gastric cancer prevention in H. pylori and gastric cancer prevalent areas.